AR099283A1 - Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4 - Google Patents
Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4Info
- Publication number
- AR099283A1 AR099283A1 ARP140104158A ARP140104158A AR099283A1 AR 099283 A1 AR099283 A1 AR 099283A1 AR P140104158 A ARP140104158 A AR P140104158A AR P140104158 A ARP140104158 A AR P140104158A AR 099283 A1 AR099283 A1 AR 099283A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- compositions
- methods
- viral diseases
- pde4 modulators
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QDZOBXFRIVOQBR-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-UHFFFAOYSA-N 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicación 1: Un método para el tratamiento o prevención de una condición o enfermedad inducida por un virus, que comprende la administración, a un paciente en necesidad de este, de una cantidad efectiva de 3-(3,4-dimetoxifenil)-3-(1-oxoindolin-2-il)propionamida (Compuesto A) o una sal, solvato o hidrato farmacéuticamente aceptables de este. Reivindicación 15: Un método para el tratamiento o prevención de una condición o enfermedad inducida por un virus, que comprende la administración, a un paciente en necesidad de este, de una cantidad efectiva de N-(2-(1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil)-3-oxoisoindolin-4-il)ciclopropancarboxamida (Compuesto B) o una sal, solvato o hidrato farmacéuticamente aceptables de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900489P | 2013-11-06 | 2013-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099283A1 true AR099283A1 (es) | 2016-07-13 |
Family
ID=51999519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104158A AR099283A1 (es) | 2013-11-06 | 2014-11-05 | Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160289188A1 (es) |
| EP (1) | EP3065778A1 (es) |
| JP (1) | JP2016540041A (es) |
| KR (1) | KR20160068981A (es) |
| CN (1) | CN105873611A (es) |
| AR (1) | AR099283A1 (es) |
| AU (1) | AU2014346877A1 (es) |
| CA (1) | CA2929539A1 (es) |
| EA (1) | EA201690937A1 (es) |
| IL (1) | IL245511A0 (es) |
| MX (1) | MX2016005808A (es) |
| PH (1) | PH12016500824A1 (es) |
| SG (1) | SG11201603469UA (es) |
| WO (1) | WO2015069711A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| CA2506442A1 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| CN1452982A (zh) * | 2003-06-25 | 2003-11-05 | 上海兴康医药研究开发有限公司 | 用于预防sars的利巴韦林黏膜给药制剂及制备方法 |
| CA2563377A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
| WO2007139150A1 (ja) * | 2006-05-30 | 2007-12-06 | The University Of Tokushima | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 |
| AU2008293532B2 (en) * | 2007-08-27 | 2014-08-28 | Kineta Four Llc | Antiviral drugs for treatment of Arenavirus infection |
| US20100080807A1 (en) * | 2008-09-26 | 2010-04-01 | National Taiwan University | Methods and Compositions for Treating Viral Hemorrhagic Fever |
| US20100297033A1 (en) * | 2009-05-21 | 2010-11-25 | Mcleay Matthew T | Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease |
| WO2011127019A2 (en) * | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
| WO2012118599A1 (en) * | 2011-02-28 | 2012-09-07 | Emory University | C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication |
-
2014
- 2014-11-05 EA EA201690937A patent/EA201690937A1/ru unknown
- 2014-11-05 AR ARP140104158A patent/AR099283A1/es unknown
- 2014-11-05 CN CN201480072359.8A patent/CN105873611A/zh active Pending
- 2014-11-05 WO PCT/US2014/064047 patent/WO2015069711A1/en not_active Ceased
- 2014-11-05 SG SG11201603469UA patent/SG11201603469UA/en unknown
- 2014-11-05 JP JP2016552461A patent/JP2016540041A/ja active Pending
- 2014-11-05 MX MX2016005808A patent/MX2016005808A/es unknown
- 2014-11-05 EP EP14805411.7A patent/EP3065778A1/en not_active Withdrawn
- 2014-11-05 KR KR1020167014535A patent/KR20160068981A/ko not_active Withdrawn
- 2014-11-05 CA CA2929539A patent/CA2929539A1/en not_active Abandoned
- 2014-11-05 US US15/034,854 patent/US20160289188A1/en not_active Abandoned
- 2014-11-05 AU AU2014346877A patent/AU2014346877A1/en not_active Abandoned
-
2016
- 2016-05-03 PH PH12016500824A patent/PH12016500824A1/en unknown
- 2016-05-05 IL IL245511A patent/IL245511A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500824A1 (en) | 2016-06-13 |
| SG11201603469UA (en) | 2016-05-30 |
| US20160289188A1 (en) | 2016-10-06 |
| EP3065778A1 (en) | 2016-09-14 |
| MX2016005808A (es) | 2016-07-18 |
| EA201690937A1 (ru) | 2017-02-28 |
| KR20160068981A (ko) | 2016-06-15 |
| IL245511A0 (en) | 2016-06-30 |
| CN105873611A (zh) | 2016-08-17 |
| CA2929539A1 (en) | 2015-05-14 |
| JP2016540041A (ja) | 2016-12-22 |
| WO2015069711A1 (en) | 2015-05-14 |
| AU2014346877A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2022009352A (es) | Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c. | |
| WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
| AR109452A1 (es) | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
| EA201692436A1 (ru) | Медицинское применение | |
| JP2015534562A5 (es) | ||
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| BR112017004798A2 (pt) | composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| AR090874A1 (es) | Formulacion | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MX2021009909A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |